Key facts
- MgShell’s last known valuation is $9.5M (Jan 2025).
- It has raised $3.1M; the latest was Seed Round ($1.3M) in Apr 2025.
- Notable investors include Club degli investitori, Andrea Giani, Bio4Dreams, Bios Line Holding, Capital Cell — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for MgShell
- ·The full record, as it builds
Funding rounds
No funding rounds for MgShell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MgShell
Developer of a magnesium-based drug delivery platform designed to improve treatment outcomes for retinal diseases. The company's platform offers biodegradable magnesium based delivery technology engineered for controlled drug release and improved biocompatibility, enhancing treatment adherence and supporting targeted therapy, enabling patients with ophthalmic conditions to experience more consistent outcomes and reduced treatment burden, enabling patients with ophthalmic conditions to receive more effective and manageable care.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2019
- Employees
- 10
- Website
- mgshell.com/
- Ownership
- Privately Held (backing)
MgShell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MgShell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MgShell in its N-PORT filings yet. We sweep new filings monthly.